In a report published Wednesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Medtronic MDT.
In the report, Morgan Stanley noted, “The quarter confirmed fears on CRM share loss and EM pressure, but both were roughly inline with expectations. Concerns notwithstanding, the key issue for Medtronic is the ability to drive comparable growth to peers. In the interim, we see the multiple discount as warranted. We remain Equal-weight.”
Medtronic closed on Tuesday at $56.19.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in